Azemiglitazone potassium

• CAT Number: I032832
• CAS Number: 1314533-27-1
• Molecular Formula: C19H16KNO5S
• Molecular Weight: 409.50
• Purity: ≥95%

Azemiglitazone potassium (MSDC-0602K), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC50 of 18.25 μM[1]. Azemiglitazone potassium modulates the mitochondrial pyruvate carrier (MPC). Azemiglitazone potassium can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance[2]. Azemiglitazone potassium, an insulin sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide[3].
Diabetic db/db and MS-NASH mice are treated with Azemiglitazone potassium by oral gavage, Liraglutide by s.c. injection, or combination Azemiglitazone potassium + Liraglutide. This combination treatment may be an effective therapeutic strategy for diabetes and non-alcoholic steatohepatitis (NASH).

Reference

[1]. Zhouji Chen, et al. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. J Biol Chem. 2012 Jul 6;287(28):23537-48.
 [Content Brief]

[2]. Jerry R Colca, et al. MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis. Expert Opin Investig Drugs. 2018 Jul;27(7):631-636.
 [Content Brief]

[3]. Dakota R Kamm, et al. Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide. J Biol Chem. Jan-Jun 2021;296:100807.
 [Content Brief]